CORESTEM Inc (166480) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CORESTEM Inc (166480) has a cash flow conversion efficiency ratio of -0.103x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.18 Billion ≈ $-2.83 Million USD) by net assets (₩40.62 Billion ≈ $27.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CORESTEM Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how CORESTEM Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 166480 current and long-term liabilities for a breakdown of total debt and financial obligations.
CORESTEM Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CORESTEM Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Harboes Bryggeri A/S
CO:HARB-B
|
0.023x |
|
Franklin Street Properties Corp
NYSE MKT:FSP
|
0.006x |
|
Bubs Australia Ltd
AU:BUB
|
-0.127x |
|
Emkay Global Financial Services Limited
NSE:EMKAY
|
-0.048x |
|
LEFORM
KLSE:0266
|
0.111x |
|
Thai Wacoal Public Company Limited
BK:WACOAL
|
-0.006x |
|
Histeel
KO:071090
|
0.001x |
|
Ittifak Holding A.S.
IS:LRSHO
|
-0.028x |
Annual Cash Flow Conversion Efficiency for CORESTEM Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of CORESTEM Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market value of CORESTEM Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩48.59 Billion ≈ $32.93 Million |
₩-21.12 Billion ≈ $-14.31 Million |
-0.435x | +45.73% |
| 2023-12-31 | ₩19.60 Billion ≈ $13.28 Million |
₩-15.70 Billion ≈ $-10.64 Million |
-0.801x | -294.34% |
| 2022-12-31 | ₩41.46 Billion ≈ $28.10 Million |
₩-8.42 Billion ≈ $-5.71 Million |
-0.203x | +1.23% |
| 2021-12-31 | ₩37.19 Billion ≈ $25.20 Million |
₩-7.65 Billion ≈ $-5.18 Million |
-0.206x | -290.05% |
| 2020-12-31 | ₩41.29 Billion ≈ $27.98 Million |
₩4.47 Billion ≈ $3.03 Million |
0.108x | +1260.00% |
| 2019-12-31 | ₩57.70 Billion ≈ $39.10 Million |
₩-538.08 Million ≈ $-364.65K |
-0.009x | +48.55% |
| 2018-12-31 | ₩62.24 Billion ≈ $42.18 Million |
₩-1.13 Billion ≈ $-764.48K |
-0.018x | +81.10% |
| 2017-12-31 | ₩65.60 Billion ≈ $44.46 Million |
₩-6.29 Billion ≈ $-4.26 Million |
-0.096x | -282.69% |
| 2016-12-31 | ₩66.73 Billion ≈ $45.22 Million |
₩3.50 Billion ≈ $2.37 Million |
0.053x | +424.60% |
| 2015-12-31 | ₩63.04 Billion ≈ $42.72 Million |
₩-1.02 Billion ≈ $-691.01K |
-0.016x | +87.47% |
| 2014-12-31 | ₩18.97 Billion ≈ $12.86 Million |
₩-2.45 Billion ≈ $-1.66 Million |
-0.129x | -- |
About CORESTEM Inc
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatm… Read more